Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1075 results about "Monocyte" patented technology

Monocytes are a type of leukocyte, or white blood cell. They are the largest type of leukocyte and can differentiate into macrophages and myeloid lineage dendritic cells. As a part of the vertebrate innate immune system monocytes also influence the process of adaptive immunity. There are at least three subclasses of monocytes in human blood based on their phenotypic receptors.

Anti-CD3 nano antibody capable of activating T cell activity as well as preparation method and application of anti-CD3 nano antibody

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.
Owner:BIOINTRON BIOLOGICAL INC

Antibacterial peptide and application thereof

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.
Owner:JIANGNAN UNIV

New application of PBMC (peripheral blood mononuclear cell)-derived cytotoxic T cell

The present invention relates to: a method for evaluating the efficacy of an anti-cancer drug, a method for screening an anti-cancer drug, a system for evaluating the efficacy of an anti-cancer drug, or a system for screening an anti-cancer drug, using a mixture of peripheral blood mononuclear cells (PBMC) and a cancer organoid. Specifically, the present invention relates to: a method for evaluating the efficacy of an anti-cancer drug, a method for screening an anti-cancer drug, a system for evaluating the efficacy of an anti-cancer drug, or a system for screening an anti-cancer drug, using a mixture of cytotoxic T cells differentiated from PBMC and cancer organoids. According to the method for evaluating the efficacy of an anti-cancer drug, the screening method, the efficacy evaluation system, or the screening system of the present invention, a tumor microenvironment, i.e. The form in which cancer cells are present in a living body, can be very closely reproduced. Furthermore, since PBMCs derived from normal individuals are used and differentiated into cancer patient-specific cytotoxic T cells, the burden of collecting biological samples such as blood and tissue samples from cancer patients can be reduced, and the efficacy of an anti-cancer drug can be evaluated with high accuracy.
Owner:ORGANOIDSCIENCES LTD

Strain for degrading aspartame, algal-bacterial symbiotic system and application of algal-bacterial symbiotic system

The invention discloses a bacterial strain for degrading aspartame, a bacterial-algae symbiotic system and application of the bacterial strain and the bacterial-algae symbiotic system, the bacterial strain is corn sphingomonas zeae NCU J1, and the preservation number of the bacterial strain is CCTCC (China Center for Type Culture Collection) NO: M 20251462. And an algal-bacterial symbiotic system is constructed by adopting an oriented symbiotic combination of the corn sphingomonas NCU J1 and the chlorella sp. The corn sphingomonas NCU J1 can metabolize an artificial sweetening agent aspartame and degradation products thereof, metabolism complementation can be achieved through an algal-bacterial symbiotic interface, and bacteria preferentially promote aspartame to be subjected to photohydrolysis to generate degradation products such as diketopiperazine derivatives. The microalgae synchronously start isomerism enzymatic reaction to convert degradation products such as diketopiperazine derivatives into low-toxicity products, the risk of secondary pollution is reduced by 40% or above compared with that of a traditional physical and chemical method, 150 mg / L aspartame can be efficiently degraded within 2 days, generation of derivatives of aspartame can be greatly reduced, secondary pollution is reduced, and the method is suitable for industrial production. And the method has a good application prospect in the aspect of rapidly treating aspartame-containing wastewater.
Owner:NANCHANG UNIV

In vitro model of inflamed intestinal barrier

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Owner:UNIVERSITE DE FRANCHE COMTE

Method for differentiating induced pluripotent stem cells into macrophages

PendingCN119662546Aavoid moral controversyHigh differentiation efficiencyBlood/immune system cellsForeign genetic material cellsCell differentationMonocyte
The invention discloses a method for differentiating induced pluripotent stem cells into macrophages. The method comprises the following steps: S1, inducing pluripotent stem cells to form embryoid bodies; s2, differentiating the embryoid body into a monocyte with CD14 expression; s3, the mononuclear cells are differentiated into macrophages with CD14 / CD11b expression; and S4, polarizing the macrophages into M1 type macrophages and / or M2 type macrophages. According to the method for differentiating the induced pluripotent stem cells into the macrophages, the cells can be effectively induced to differentiate towards the macrophages, the induced pluripotent stem cells are subjected to directional differentiation culture in a short time to obtain the macrophages, and the generated macrophages express CD14 and CD11b and have remarkable phagocytic activity on yeast glycan. The method is of great significance to large-scale production of macrophages.
Owner:SHANDONG YINFENG LIFE SCIENCE RESEARCH INSTITUTE +1

Construction method of anti-programmed death protein-1 monoclonal antibody treatment response prediction model

The invention provides a construction method of an anti-programmed death protein-1 monoclonal antibody treatment response prediction model, and belongs to the technical field of construction methods of prediction models. The method comprises the following steps: acquiring a blood sample of a non-small cell lung cancer patient; extracting peripheral blood mononuclear cells of the blood sample of the patient before and after the treatment of the anti-programmed death protein-1 monoclonal antibody; sequentially carrying out treatment through the steps of protein extraction, reductive alkylation and enzymolysis to obtain a sample peptide fragment; performing basic characteristic analysis and function annotation to obtain a protein spectrum and a modification spectrum of peripheral blood mononuclear cells of the non-small cell lung cancer patient treated by the anti-programmed death protein-1 monoclonal antibody; screening by utilizing machine learning to obtain a biomarker; and monitoring to obtain the anti-programmed death protein-1 monoclonal antibody treatment response prediction model. The method can be used for predicting the treatment effect of the anti-programmed death protein-1 monoclonal antibody of a non-small cell lung cancer patient.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

New application of niclosamide

The invention belongs to the technical field of medicines, and particularly discloses application of niclosamide in preparation of a medicine for treating epididymis and testis fibrosis caused by bacterial infection. A UPEG-mouse epididymis / orchitis model is firstly constructed, a result shows that a monocyte subset highly expressed by S100a4 appears in a testis, the group of cells mainly express CD11b monocyte characteristics in the early stage when entering the testis, and the group of cells are partially converted into F4 / 80 + and alpha-SMA + fibroblast characteristics in the later stage. A myeloid macrophage knockout mouse is used for constructing a UPEG-epididymis / orchitis model, and the fibrosis degree of testis and epididymis is obviously reduced; a molecular mechanism shows that S100a4 can strengthen a TGF beta-STAT3 signal channel to promote the transformation of macrophages to fibroblasts, and niclosamide can inhibit the process. Mouse in-vivo experiment results show that niclosamide can obviously inhibit UPEG-mouse epididymis and testis fibrosis.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Reagent for rapidly distinguishing bacterial virus infection and application

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.
Owner:SUZHOU ZHIYAN MEDICAL TECHNOLOGY CO LTD

In-vitro skin blood vessel immune model as well as preparation method and application thereof

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.
Owner:YUNNAN YUNKE CHARACTERISTIC PLANT EXTRACTION LABORATORY CO LTD +1

Depression diagnosis marker and application thereof

The invention provides a depression diagnosis marker which is selected from one or more of immune cell Trem1 classical mononuclear cells, B cells, CD36 mononuclear cells, HLADR mononuclear cells, Th17, Treg, cell factors CXCL14, VEGFR1IL-1, RII, RANK, XEDAR, GITR, CRTAM, IL-11, IGFBP-2 and Fetuin A. The depression diagnosis marker has high MDD curative effect prediction efficiency. The invention further discloses application of the depression diagnosis marker in preparation of products for diagnosing depression, and the depression diagnosis marker has high MDD diagnosis value.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT) +1

Quality control substance for lymphocyte subpopulation analysis and preparation method thereof

The invention relates to the technical field of medical quality control products, in particular to a quality control substance for lymphocyte subpopulation analysis and a preparation method thereof, and the quality control substance comprises human monocyte simulation particles, human granulocyte simulation particles, human lymphocyte simulation particles, human erythrocyte simulation particles, human platelet simulation particles and a preserving fluid, adding the human monocyte simulation particles, the human granulocyte simulation particles, the human lymphocyte simulation particles, the human erythrocyte simulation particles and the human platelet simulation particles into a preserving fluid, and uniformly mixing according to the concentration of the human body particles, so as to obtain the quality control substance for lymphocyte subpopulation analysis. Compared with the prior art, the quality control substance for lymphocyte subpopulation analysis and the preparation method thereof have the advantages that the preparation method is simple to operate, small in batch difference and good in stability, and can be applied to quality control in the field of detection of quality control substances for flow cytometry lymphocyte subpopulation analysis.
Owner:BEIJING WEIGONG MEDICAL TECH CO LTD

Methods for enhanced nucleic acid delivery

A method for delivery of a nucleic acid. comprising administering a lipid nanoparticle composition loaded with the nucleic acid to a subject in which monocytes and / or macrophages have been depleted. thereby delivering the nucleic acid into the subject, the method may more particularly be practiced according to the following steps: a) depleting monocytes and / or macrophages in a subject: and b) administering a lipid nanoparticle composition loaded with the nucleic acid to the subject, thereby delivering the nucleic acid into the subject.
Owner:CORNELL UNIVERSITY

Applicable population screening method and application of glioma dry-like cell sensitized DC vaccine

The invention provides an applicable population screening method and application of a glioma dry-like cell sensitized DC vaccine, peripheral blood of a patient before and after inoculation of the glioma dry-like cell sensitized DC vaccine is obtained, mononuclear cells are extracted, CD8 + T cells are respectively separated from the mononuclear cells through a magnetic bead sorting method, and the CD8 + T cells are separated from the mononuclear cells. The method comprises the following steps: uniformly inoculating CD8 < + > T cells into an ELISPOT cell culture plate coated with an IFN-gamma antibody for culture, respectively setting an experimental group and a positive control group for culture, adding A2B5 < + > glioma cell lysis buffer into the experimental group and adding phytohemagglutinin into the positive control group, and carrying out ELISPOT staining on the cultured cells to obtain the secretion amount of FN-gamma before and after treatment of a patient. According to the secretion amount of the FN-gamma, patients with specific immune response to the glioma dry-like cell sensitization DC vaccine are screened, so that the glioma dry-like cell sensitization DC vaccine is conveniently popularized and applied, and the immune mechanism of the glioma dry-like cell sensitization DC vaccine is researched.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

ELISA kit for distinguishing listeria monocytogenes and / or listeria ivanovii infection as well as preparation method and application of ELISA kit for distinguishing listeria monocytogenes and / or listeria ivanovii infection

The invention discloses an indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection kit for distinguishing host infected Listeria monocytogenes and / or Listeria ivanovii. The coating antigens are respectively a recombinant listeria monocytogenes surface protein ActA, a serotype 4h listeria monocytogenes and listeria ivanovii common outer membrane protein SmcL and a listeria ivanovii specific outer membrane protein I-inlH, indirect ELISA methods are respectively established based on the three antigens, the three detection methods are combined to detect the content of the listeria monocytogenes, and the content of the listeria ivanovii can be detected. The levels of the ActA antibody, the SmcL antibody and the I-inlH antibody in a clinical serum sample can be effectively monitored, and the detection on the listeria monocytogenes caused by the listeria monocytogenes and / or the listeria ivanovii is realized. The kit is relatively high in sensitivity, strong in specificity and good in stability, and an effective method is provided for epidemiological investigation and diagnosis of listeria monocytogenes.
Owner:YANGZHOU UNIV

Monocyte or macrophage compositions with enhanced Anti- tumor activity and uses thereof

Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered monocytes or engineered monocyte-derived macrophages that overexpress ID3 for the treatment of cancer.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +2

Application of GPR161 as diagnosis marker and treatment target of acute distress syndrome

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.
Owner:ANHUI MEDICAL UNIV

ADCP biological activity detection method based on single luciferase

The invention discloses a monoluciferase-based ADCP biological activity detection method, which comprises the following steps: separating a mononuclear cell from a human peripheral blood mononuclear cell as an effector cell, phagocytizing a Raji cell transfected by Luciferase as a target cell by the mononuclear cell, acidifying and degrading the Raji cell in a phagocytic body, and degrading the Luciferase so as to attenuate a light-emitting signal, so that the ADCP biological activity is detected. The ADCP biological activity of the antibody therapeutic drug is accurately quantified by detecting the weakening of the light-emitting signal. According to the present invention, the method only needs to separate the mononuclear cells and perform Luciferase infection on the target cells, and only needs to add the luciferase substrate after the phagocytosis process, such that the luminescence value can be read by using the microplate reader, the operation process is simple, the steps are less, the time consumption is short, the high-throughput screening is achieved, and the new direction is provided for the ADCP detection.
Owner:NEOMAB BIOTECHNOLOGY CO LTD

Collection, genome editing, and washing of T-cell lymphocytes

Blood from a blood source is drawn into a fluid flow circuit. A mononuclear cell product is separated from the blood, followed by at least a portion of the mononuclear cell product being conveyed into an electroporation device without disconnecting the blood source from the fluid flow circuit. The electroporation device opens pores in a membrane of at least one of the cells of the mononuclear cell product to allow DNA material (which is added to the mononuclear cell product prior to electroporation) to enter and modify the genome of the cell. At least a portion of the modified mononuclear cell product is returned to the blood source. The mononuclear cell product may be washed prior to being conveyed into the electroporation device. The modified mononuclear cell product may be washed after exiting the electroporation device.
Owner:FENWAL INC

Double-target portable detection method for Listeria monocytogenes by Argonaute-mediated reverse fluorescence enhanced lateral flow technology and application of double-target portable detection method for Listeria monocytogenes by Argonaute-mediated reverse fluorescence enhanced lateral flow technology

The invention belongs to the technical field of microbiological detection, and discloses a method for realizing dual, rapid and portable detection of Listeria monocytogenes by integrating PfAgo cutting and LAMP amplification by virtue of a fluorescence and reverse fluorescence enhanced lateral flow technology, and the method is based on an Argonaute combined isothermal amplification detection technology, integrates a signal amplification system of PfAgo cutting and LAMP isothermal amplification, and realizes rapid and portable detection of Listeria monocytogenes by virtue of a fluorescence and reverse fluorescence enhanced lateral flow technology. And the reverse fluorescence lateral flow technology is combined, so that the listeria monocytogenes can be sensitively, selectively and accurately detected on site in a short time. According to the detection method based on the visual reverse fluorescence test strip, visual and reverse fluorescence mutual verification for rapid and ultra-sensitive detection and application of Listeria monocytogenes can be realized by combining visual colorimetry and a reverse fluorescence lateral flow technology, dependence on a large instrument is not needed, the cost is relatively low, the operation is simple and convenient, and the detection method can be applied to rapid and ultra-sensitive detection of Listeria monocytogenes. And portable on-site detection of the food-borne pathogenic bacteria can be realized.
Owner:TIANJIN UNIV OF SCI & TECH

Computer-implemented method and system for diagnosing diseases that affect morphological characteristics and the cytoplasmic complexity of blood cells

A computer-implemented method for diagnosing diseases that affect the morphological characteristics and the cytoplasmic complexity of blood cells, the method comprising: a) obtaining blood parameters from at least one patient, the blood parameters comprising at least two measured properties of individual cells from full blood analysis, the individual cells comprising leukocytes, the measured properties of the leukocytes comprising the size and granularity of the cytoplasm and the structure of the cell nucleus; b) creating at least one scatter plot, each axis of the scatter plot comprising a different measured property of the individual cells; c) ascertaining at least one cluster in at least one scatter plot, the clusters comprising the subpopulations of leukocytes, the subpopulations comprising monocytes, lymphocytes, basophils, neutrophils and eosinophils; d) combining the property elements of the ascertained clusters to form a 1-dimensional global vector, the arrangement of the property elements in the global vector comprising an arrangement by associated cluster; e) reducing the dimension of the global vector; f) diagnosing at least one disease by means of an ensemble, the ensemble comprising at least one machine learning model and at least one deep learning model, the at least one machine learning model receiving at least one reduced global vector as an input variable and the at least one deep learning model receiving at least one scatter plot image as an input variable; and g) automatically generating a report which comprises at least one result of the diagnosis of at least one disease.
Owner:ROBOTDREAMS GMBH

Application of compound in preparation of medicine for preventing, relieving, adjunctively treating or treating lung injury

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.
Owner:SHANGHAI SIMR BIOTECHNOLOGY CO LTD

Method for expansion and maintenance of NK cells for immunotherapy

The present invention discloses a method for expansion of natural killer (NK) cells or CAR-NK cells using peripheral blood mononuclear cells (PBMCs) and culturing the cells in a medium comprising a feeder layer having a population of mesenchymal stem cells (MSCs) with disrupted or deleted MHC class I gene and / or MHC class II gene and a heterologous gene for expressing Interleukin-21 (IL-21), and Interleukin-2 (IL-2). The present disclosure further provides a method and a model for evaluating natural killer (NK) cells or CAR-NK cells using tester line comprising induced Pluripotent stem cells (iPSCs) comprising disrupted or deleted MHC class I gene and / or MHC class II gene and a heterologous gene encoding a tumor antigen.
Owner:NKURE THERAPEUTICS PTE LTD

Monoclonal antibody and a method thereof

PendingUS20240417483A1Nervous disorderAntipyreticAntiendomysial antibodiesScavenger receptor
The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
Owner:BIOCON LTD +1

Detection of sepsis using hematology parameters

This disclosure describes methods of and systems for screening for sepsis or septic shock in a patient and methods of ruling out sepsis or septic shock in a patient using white blood cell count (WBC), a monocyte cell population parameter, or neutrophil-to-lymphocyte ratio (NLR), or a combination thereof, in the blood sample from the patient.
Owner:BECKMAN COULTER INC +1

Initialization agent and kit for initializing blood cells derived from peripheral blood, and method for initializing the same

According to one embodiment, an initialization agent is for initializing blood cells derived from peripheral blood. The initialization agent includes an initialization factor group for producing iPS cells by initializing a group of blood cells including mononuclear cells derived from peripheral blood, and a group of lipid nanoparticles that encapsulate the initialization factor group. The lipid nanoparticles have a component of at least or more of 40% FFT-10 and FFT-20. FFT-10 and FFT-20 are included in equal amounts.
Owner:KK TOSHIBA +1

Mononuclear cell for treating sepsis cardiomyopathy and application thereof

The invention provides a mononuclear cell for treating sepsis cardiomyopathy, and also relates to application of the mononuclear cell in preparation of drugs for improving sepsis and sepsis cardiomyopathy. The mononuclear cell provided by the invention can have a better targeted enrichment characteristic, so that the effective rate of treatment is improved, and meanwhile, toxic and side effects caused by non-specific distribution of drugs are reduced. Besides, the mononuclear cells are derived from the body of a healthy body, so that the mononuclear cells are more stable in metabolism, higher in absorption efficiency and more excellent in enrichment effect when acting on the body, and the technical problems that in-vivo half-life period of drugs is short and catabolism is easy in the prior art are solved.
Owner:ZHEJIANG UNIV

Gracilaria heteroclada low-molecular-weight polysaccharide as well as preparation method and application thereof

The invention discloses a gracilaria variegata low-molecular-weight polysaccharide GBP-1a, the monosaccharide is composed of 82.8% of galactose and 17.2% of glucose through structural analysis, the molecular weight of the uniform polysaccharide is 2887Da, and the polysaccharide has no toxicity to THP-1 mononuclear cells and THP-1 macrophages within a set concentration range through activity detection; and after the polysaccharide is subjected to immune training on THP-1 mononuclear cells and THP-1 macrophages, the immune response of the polysaccharide is obviously higher than that of cells which are not subjected to polysaccharide immune training, so that the training of the polysaccharide is preliminarily deduced to possibly enable the cells to generate acquired immunity similar to vaccines.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Preparation method of DC cell and application of DC cell in preparation of anti-tumor cell preparation

The invention provides a preparation method of DC cells. The preparation method is especially suitable for rapidly obtaining high-purity and high-functional-activity DC cells. The method comprises the steps of separation from peripheral blood mononuclear cells (PBMC), induction culture, maturation treatment and the like, maturation of the dendritic cells is promoted by introducing an anti-CD47 single-domain antibody or LPS, and the immunocompetence of the dendritic cells is remarkably improved. The method is further applied to preparation of an anti-tumor cell preparation, the capability of activating tumor specific T cells by tumor antigen-loaded DC cells can be remarkably enhanced, and the killing activity of the T cells to tumor cells is improved. The preparation method provided by the invention overcomes the defects in the prior art, has the advantages of high efficiency, safety and stability, and can provide a more reliable cell therapy scheme for tumor immunotherapy.
Owner:LANCE CELL BIOTECHNOLOGY (GUANGZHOU) CO LTD